PLX vs. JSPR, TNYA, AURA, TRML, MGTX, STRO, AVXL, REPL, SOPH, and SLDB
Should you be buying Protalix BioTherapeutics stock or one of its competitors? The main competitors of Protalix BioTherapeutics include Jasper Therapeutics (JSPR), Tenaya Therapeutics (TNYA), Aura Biosciences (AURA), Tourmaline Bio (TRML), MeiraGTx (MGTX), Sutro Biopharma (STRO), Anavex Life Sciences (AVXL), Replimune Group (REPL), SOPHiA GENETICS (SOPH), and Solid Biosciences (SLDB). These companies are all part of the "biological products, except diagnostic" industry.
Protalix BioTherapeutics (NYSE:PLX) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability, community ranking and media sentiment.
16.5% of Protalix BioTherapeutics shares are owned by institutional investors. Comparatively, 79.9% of Jasper Therapeutics shares are owned by institutional investors. 5.0% of Protalix BioTherapeutics shares are owned by insiders. Comparatively, 2.7% of Jasper Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Protalix BioTherapeutics presently has a consensus target price of $10.00, indicating a potential upside of 754.70%. Jasper Therapeutics has a consensus target price of $64.29, indicating a potential upside of 168.08%. Given Protalix BioTherapeutics' higher probable upside, equities analysts clearly believe Protalix BioTherapeutics is more favorable than Jasper Therapeutics.
Jasper Therapeutics received 21 more outperform votes than Protalix BioTherapeutics when rated by MarketBeat users. Likewise, 83.87% of users gave Jasper Therapeutics an outperform vote while only 62.50% of users gave Protalix BioTherapeutics an outperform vote.
Protalix BioTherapeutics has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500. Comparatively, Jasper Therapeutics has a beta of 2.25, meaning that its stock price is 125% more volatile than the S&P 500.
Protalix BioTherapeutics has higher revenue and earnings than Jasper Therapeutics. Jasper Therapeutics is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Jasper Therapeutics had 2 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 3 mentions for Jasper Therapeutics and 1 mentions for Protalix BioTherapeutics. Jasper Therapeutics' average media sentiment score of 1.36 beat Protalix BioTherapeutics' score of -0.67 indicating that Jasper Therapeutics is being referred to more favorably in the news media.
Protalix BioTherapeutics has a net margin of 11.48% compared to Jasper Therapeutics' net margin of 0.00%. Protalix BioTherapeutics' return on equity of 19.48% beat Jasper Therapeutics' return on equity.
Summary
Protalix BioTherapeutics beats Jasper Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Protalix BioTherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PLX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Protalix BioTherapeutics Competitors List
Related Companies and Tools
